Corporate | 30 September 2014 07:24
DGAP-News: Evotec AG / Key word(s): Miscellaneous
30.09.2014 / 07:24
---------------------------------------------------------------------
Hamburg, Germany - 30 September 2014: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target
collaboration with Bayer HealthCare ("Bayer") has reached an important
milestone for the transition of a molecule into pre-clinical development
for the treatment of endometriosis.
This milestone was achieved under the agreement between Evotec and Bayer
signed in October 2012. The goal of this collaboration is to develop three
clinical candidates within the five year alliance. Both parties contribute
innovative drug targets and high-quality technology infrastructures and
share the responsibility for early research and pre-clinical
characterisation of potential clinical candidates in the disease area of
endometriosis.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
very pleased to achieve this validation of our joint work with the Bayer
team. Both teams of scientists have developed a tremendous relationship and
collaborative way of working and we look forward to continue this
productive work and focus our efforts on bringing forward new drug
candidates to tackle this significant disease."
Further financial details were not disclosed.
ABOUT ENDOMETRIOSIS
Endometriosis affects an estimated 176 million women worldwide or 10% of
women of reproductive age. It is caused by the abnormal growth of tissue
similar to that which lines the uterus (endometrial tissue) in locations
outside of the uterine cavity, where it causes ectopic lesion growth and
debilitating pain. Endometrial growth is commonly found on the ovaries and
pelvic peritoneum, potentially involving other organs of the pelvic cavity
as e.g. bladder, bowel, and the rectovaginal space. There is no known cure
for endometriosis and most available drug treatments have certain
limitations. Endometriosis is a highly complex and heterogeneous disease
and there is still a high unmet medical need for innovative therapies which
address the individual needs of affected women. The disease can greatly
impact a woman's social, professional and personal life, and women with
endometriosis often experience a higher incidence of depression and
emotional distress due to the uncertainty of diagnosis, unpredictability of
symptoms and living a normal life. Find more information at
http://endometriosisfoundation.org or http://endometriosis-league.eu/en.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners including
Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing
development partnerships and product candidates both in clinical and
pre-clinical development. These include partnerships with Boehringer
Ingelheim and MedImmune in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
http://www.evotec.com/.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
---------------------------------------------------------------------
30.09.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
289315 30.09.2014